Список проголосовавших за комментарий " GTX +10.2% pre-market after reporting Q4 results & providing a corporate update (5.28)<ul><li>GTX reported Q4 GAAP EPS of ($0.44), vs the ($0.57) single analyst estimate.</li><li>As of Dec 31, 2016, cash and short-term investments were $21.9 million compared to $29.3 million at Dec 31, 2015.</li><li>Corporate update:<ul><li><strong>AR+TNBC:</strong> The co expects to have sufficient data from Stage 1 of the trial by the second quarter of 2017 to determine if patient enrollment should continue into Stage 2 of the trial.</li><li><strong>Stress Urinary Incontinence:</strong> The co expects to have top-line results from the trial in the third quarter of 2017.</li><li><strong>Castration-Resistant Prostate Cancer:</strong> It is anticipated that a first in human clinical trial of a SARD will be initiated during the second half of 2017.</li></ul></li></ul>"